Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALSAM-3 KarXT Long-term Safety in Bipolar I Mania
jRCT2041250099Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in bipolar I disorder, sponsored by Bristol Myers Squibb. Primary endpoint: Treatment-emergent adverse events. Started Sep 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on jRCT2041250099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250099.